EGFR and breast cancer: Dysregulation of RTKs, such as members of epidermal growth factor receptor (EGFR) family, or overexpression of their ligands is frequently found in breast cancer [68,69], glioblastomas (GBM) [70,71] and non-small cell lung carcinoma (NSCLC) [72,73], and results in sustained pro-proliferative, pro-invasive and pro-survival signaling [68,69,70,71,72,73,74,75,76,77,78,79,80,81,82].